Key result
Antenatal dexamethasone administration significantly increased fetal heart rate variability from a baseline of 8.33 to 13.75 after the first dose and 17.15 after the fourth dose.
Why the study?
The study was conducted to analyse the effects of antenatal dexamethasone on fetal heart rate variability in mothers between 30-37 weeks of gestation at risk of preterm delivery, and corroborate presenting symptoms with delivery mode and perinatal outcomes.
Does dexamethasone increase fetal heart rate variability in pregnant women at risk of preterm delivery?
Observational (n=52)
No
Does dexamethasone increase fetal heart rate variability in pregnant women at risk of preterm delivery?
Mean Difference: 5.42
Absolute Event Rate: 13.75% vs 8.33%
p-value: p=<0.001
Antenatal dexamethasone administration in women at risk of preterm delivery increases fetal heart rate variability without significantly decreasing baseline fetal heart rate.
Background: To analyse the effects of antenatal dexamethasone on fetal heart rate variability (fHRV), when administered to mothers between 30-37 weeks of gestation, at risk of preterm delivery and corroborate presenting maternal symptoms with mode of delivery and perinatal outcomes. Method: Prospective observational study conducted for 1 Year among pregnant women with gestation between 30 completed weeks to 36 weeks 6 days, with symptoms suggesting risk of preterm delivery. The sample size calculated was 52. Dexamethasone phosphate, 24 mg in 4 divided doses, was administered as intramuscular injections 12 hours apart. NST tracings were taken at three points-before first dose, one hour after first dose and one hour after the fourth dose. Chi-square test and Paired t test was applied, p<0.05 was considered statistically significant. Results: Strong correlation was found between antenatal dexamethasone administration and fHRV (p<0.05) which increased after administration of the first dose of dexamethasone compared to its value prior to administration. There was a further increase after the fourth dose. Conclusions: Dexamethasone is associated with increase in fHRV evident on non-stress test recordings, without significant decrease in baseline fetal heart rate.
No takes yet. Share an insight, caveat, or question.
Ananya et al. (2023) conducted an observational in Risk of preterm delivery (n=52). Dexamethasone vs. Pre-dexamethasone baseline was evaluated on Fetal heart rate variability (fHRV) after 1st dose (MD 5.42, p=<0.001). Antenatal dexamethasone administration significantly increased fetal heart rate variability from a baseline of 8.33 to 13.75 after the first dose and 17.15 after the fourth dose.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: